The study uses Mendelian randomization to examine the relationship between 14 micronutrients and 22 cancer outcomes, finding significant associations between higher magnesium and vitamin B12 levels and increased risks of breast and colorectal cancers, respectively.
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sabestomig?
Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma.